T2Candida panel is performed on the fully automated T2Dx instrument in whole blood K2EDTA specimens and is able to detect 5 Candida spp.
T2Dx
T2Candida panel is a novel qualitative diagnostic platform that was recently approved by the US Food and Drug Administration (FDA) for diagnosis of candidemia with a mean time to species identification of less than 5 h. 
FDA
T2Candida panel is performed on the fully automated T2Dx instrument in whole blood K2EDTA specimens and is able to detect 5 Candida spp.
K2EDTA
T2Candida panel is a novel qualitative diagnostic platform that was recently approved by the US Food and Drug Administration (FDA) for diagnosis of candidemia with a mean time to species identification of less than 5 h.  T2Candida panel is performed on the fully automated T2Dx instrument in whole blood K2EDTA specimens and is able to detect 5 Candida spp. By combining magnetic resonance with molecular diagnostics, T2Candida panel amplifies DNA and detects the amplified product by amplicon-induced agglomeration of supermagnetic particles and T2 Magnetic Resonance (T2MR) measurement.  Here we describe the materials and methods needed to diagnose candidemia with the T2Candida panel.
T2Candida
By combining magnetic resonance with molecular diagnostics, T2Candida panel amplifies DNA and detects the amplified product by amplicon-induced agglomeration of supermagnetic particles and T2 Magnetic Resonance (T2MR) measurement. 
T2MR